Off-label

The FDA's Actions Open Door to 'Truthful, Non-Misleading' Marketing

The FDA's Actions Open Door to 'Truthful, Non-Misleading' Marketing

By

That change is coming about in the wake of a string of First Amendment-based losses for the FDA in federal courts around the country.

Five things for pharma marketers to know: Wednesday, March 9, 2016

Five things for pharma marketers to know: Wednesday, March 9, 2016

By

Amarin settles with the FDA over off-label promotion suit; mobile apps often share medical information with third parties; drug spending rose 12% in 2014

2016 May Bring More Warning Letters, Guidance from FDA

2016 May Bring More Warning Letters, Guidance from FDA

It is worth noting that the FDA sent only nine warning letters last year, all focused on well-recognized violations, such as minimization of risk information and unsubstantiated claims.

The FDA settles with Pacira, rescinds warning letter

The FDA settles with Pacira, rescinds warning letter

By

The FDA withdrew a 2014 warning letter related to Pacira Pharmaceuticals' marketing of its painkiller Exparel as part of a settlement reached by both parties this week.

Industry watches Pacira's off-label case against the FDA

Industry watches Pacira's off-label case against the FDA

By

The drugmaker had sued the FDA in September over marketing restrictions for its painkiller, Exparel.

Off-label cases against the FDA move forward

Off-label cases against the FDA move forward

By

Amarin begins legally promoting off-label uses of its prescription fish-oil drug, while Pacira sues the FDA over the label for its pain drug, Exparel.

Five things for pharma marketers to know: Wednesday, September 9, 2015

Five things for pharma marketers to know: Wednesday, September 9, 2015

By

Pacira sues the FDA over marketing limitations; nonprofit says PCSK9 inhibitors are priced too high; GSK's Breo fails to extend life

Amgen settles off-label case with states

Amgen settles off-label case with states

By

State attorneys general accused the drugmaker of violating state consumer protection laws.

What to expect in wake of the Amarin ruling: more truthful off-label talk from pharma

What to expect in wake of the Amarin ruling: more truthful off-label talk from pharma

By

But don't expect the floodgates to open. Marketers still have to take a legal route to promote such information.

Judge grants relief to Amarin in off-label case

Judge grants relief to Amarin in off-label case

By

The decision, a setback for the FDA, allows the drugmaker to move forward with plans to legally promote some off-label information.

21st Century Cures, Amarin Court Case Advance

21st Century Cures, Amarin Court Case Advance

Pharma's efforts to evolve restrictions about off-label marketing move forward.

House expected to vote on 21st Century Cures

House expected to vote on 21st Century Cures

By

The legislation would allow drugmakers to share information about their products beyond what is included on the FDA-approved label.

Amicus briefs pile up in Amarin lawsuit

The Medical Information Working Group and the Washington Legal Foundation filed briefs in support of Amarin.

Amarin lawsuit about more than fish oil

Amarin lawsuit about more than fish oil

By

An FDA letter says there was no need to go to court but experts tell MM&M this lawsuit highlights an issue that is bigger than a single pill.

21st Century Cures bill advances to House floor

21st Century Cures bill advances to House floor

By

The legislation would allow drugmakers to share economic information with payers beyond what is included on the FDA-approved label.

Lawmakers advance 21st Century Cures draft; proposal would allow sharing of off-label economic data

Lawmakers advance 21st Century Cures draft; proposal would allow sharing of off-label economic data

By

The draft would allow drugmakers to share off-label economic data with payers, a practice that until now has been considered taboo, and require the FDA to assess patient experience data in regulatory decisions, in addition to boosting funding for the NIH.

Five things for pharma marketers to know: Thursday, March 12

Five things for pharma marketers to know: Thursday, March 12

By

The SEC said some company drug prices can be made public, 23andMe launched an R&D division, and Public Citizen is asking the FDA to withdraw a proposal it says will undermine drug safety information.

Study shows Lucentis at Eylea disadvantage

Study shows Lucentis at Eylea disadvantage

By

An NIH study shows possible limit to Lucentis's appeal.

Five things for pharma marketers to know: Wednesday, February 11

Five things for pharma marketers to know: Wednesday, February 11

By

BMS loses breakthrough therapy status, Gilead's pricing comes under fire in Europe, and pharma fights Italy's off-label Avastin use.

Roche seeks new Lucentis indication

Roche seeks new Lucentis indication

By

The company is seeking a diabetic retinopathy indication.

Pfizer settles off-label Rapamune case for $35M

Pfizer settles off-label Rapamune case for $35M

By

The drugmaker will dole out $35 million in a deal with 41 state attorneys general after a New York County Supreme Court judge said Wyeth allegedly promoted the immuno-suppressive drug improperly.

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

By

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic communications environment.

Study: sales rep limits reduce off-label prescriptions

Study: sales rep limits reduce off-label prescriptions

By

Researchers found that limiting sales rep access and interactions reduces off-label prescriptions for the previously detailed drugs, while also upping off-label prescriptions of the drugs that had not been promoted.

Off-label guidance may not be publishing boon

Off-label guidance may not be publishing boon

By

The FDA's proposed upgrade to its off-label distribution guidelines has some new features, but experts say it is unclear if this means more dollars will flow toward reprints.

Lidoderm reps inflated drug's uses

Lidoderm reps inflated drug's uses

By

Endo settled off-label charges for $192 million, resolving civil "whistleblower" suits filed by two sales reps and a physician.

J&J marketing triggers $2.2B payout

J&J marketing triggers $2.2B payout

By

The company will shell out $2.2 billion over allegations of marketing misconduct for Risperdal, Invega and Natrecor.

Business briefs: Abbott, IMS Health, Boehringer, plus healthcare reform

Abbott's Depakote lawsuits roll on; IMS buys mobile health firm's assets; BI shutters a chemical plant; and the healthcare reform back-and-forth continues.

Business briefs: Pfizer, GlaxoSmithKline, AstraZeneca, Mallinckrodt

Pfizer settles Rapamune lawsuits; Moody's downgrades GSK; Astrazeneca pursues anemia medication; Mallinckrodt drugs gets priority review

Business Briefs Merck, GSK, Novo, Walgreen, Epocrates, Doximity

HPV vaccine price cut; Merck files new allergy med with FDA; GSK pursues online transparency; Walgreens ready for greater nurse autonomy; Epocrates ranks high among docs with tablets.

Novartis: lawsuits, layoffs and, by the way, earnings

By

It was an all-in-one news day for the drug maker which, by the way, saw sales rise 2% for the first quarter, compared to the same period last year.

OPINION

Email Newsletters